CTIS2023-504807-94-00招募中1 期
STX-478-101
Scorpion Therapeutics Inc.0 个研究点目标入组 220 人开始时间: 2023年8月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study of STX-721 in participants with non-small cell lung cancer with certain mutationsocally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104CTIS2023-506759-51-00Scorpion Therapeutics Inc.112
招募中
1 期
A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell LymphomasRelapsed/refractory (R/R) B-cell and T-cell lymphomasMedDRA version: 20.0Level: PTClassification code: 10003899Term: B-cell lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2022-502299-21-00Step Pharma189
进行中（未招募）
1 期
A phase Ib study to investigate the safety and effect of BR-003Patients planned for open or percutaneous posterior spinal stabilisation with 4 or 6 pedicle screws with a diameter of 5 to 7.5 mm (inclusive), with or without concomitant posterolateral fusion, vertebral augmentation, intervertebral body fusion devices, osteotomies, and posterior decompression.CTIS2024-516338-37-00SentryX B.V.12
进行中（未招募）
1 期
A Randomized, Open-label, Single Dose, 3-Period, 6-Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Apraglutide Versus the Reference Formulation Following Subcutaneous Administrations.CTIS2023-504430-22-00VectivBio AG33
进行中（未招募）
1 期
A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac DiseaseCeliac diseaseCTIS2022-502817-27-00Teva Branded Pharmaceutical Products R&D Inc.20